PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1993, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Sustitute for form 1449A/PTO

MFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

	Complete if Known	RECEIVED
Application Number	09/881,050	- VED
Filing Date	June 15, 2001	SEP 9.0
First Named Inventor	Croze et al.	SEP 2 6 2002
Group Art Unit	Unassigned	TEOLICE
Examiner Name	Unassigned	TECH CENTER 1600/2900
Attorney Docket Number	Berlx-88	200/2900

	U.S. PATENT DOCUMENTS						
		U.S. Patent Docu	tent Document		Date of Publication of		
Examiner Initials *	iner Cite		of Cited Document	Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevan Passages or Relevant Figures Appear		
	ļ						
	<u> </u>						
		 					
	-	ļ					
··-				•			
	_	-			·		
		 					
							
		+					
		 		 			
		 					
		 					
			- 				
		<u> </u>		 			
		† · · · · ·	· · · · · · · · · · · · · · · · · · ·				

FOREIGN PATENT DOCUMENTS							
Examiner	Cito	For	eign Patent Document	Name of Patentee	Date of Publication of	Pages, Columns, Lines,	
Initials*	si Oile	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T ₆			
01/-	1	wo	00 17361		03-30-2000		
71	2	WO	95 30435		11-16-1995		
	3	WO	99 62542		12-09-1999		
	4	WO	99 29863		06-17-1999		
V	5	wo	01,79289		10-25-2001		
		 					
		 					
-					-		

Examiner Signature	1/11-(hs	Date Considered	12 A + 2000

EXAMINER: Initial if eference considered, whether or not citation is in conformance with MPEP 609. Draw line thready citation if not in conformance and not considered include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark hee if English language Translation is attached.

j			
/	type a plus sign (+) inside this box	→	[+]
	4.5	•	

		PTO	D/SB/08A	(08-00)
Approved	for use through	10/31/2002	OMB OCC	1.0024

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of 2

	Complete if Kr	nown
Application Number	09/881,050	RECEIVED
Filing Date	June 15, 200	1
First Named Inventor	Croze et al.	SEP 2 6 2002
Group Art Unit	Unassigned	361 & 8 200 2
Examiner Name	Unassigned	TEOL OF LITTER
Attorney Docket Number	Berlx-88	TECH CENTER 1620/290(

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
M	6	H.S. PANITCH ET AL., "CLINICAL TRIALS OF INTERFERONS IN MULTIPLE SCLEROSIS: WHAT HAVE WE LEARNED?" JOURNAL OF NEUROIMMUNOLOGY, July 1, 1993, Vol. 46, No. ½, pp. 155-164			
	7	JOHNSON, K.P., "ROLE OF INTERFERONS IN DEMYELINATING DISEASE", <u>JOURNAL OF NEURAL</u> TRANSMISSION, SUPPLEMENTUM, 1997, Vol. 49,pp. 111-115			
7					
		·			

Examiner Signature	0/12/11	Date Considered (2)	
•			

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line though citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.